IL-12 inhibits postoperative residual tumor growth in murine models of sarcoma and renal carcinoma

• Published in: Anti-cancer drugs Vol. 32; no. 10; pp. 1003 - 1010
• Main Authors: Ding, Huiqin, Yuan, Shoujun, Wang, Jiangang, Qin, Huan, Han, Yantao
• Format: Journal Article
• Language: English
• Published: England Wolters Kluwer Health, Inc. All rights reserved 01-11-2021
• Subjects: Animals; Antineoplastic Agents - pharmacology; Body Weight - drug effects; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans; Interleukin-12 - pharmacology; Kidney Neoplasms - drug therapy; Kidney Neoplasms - surgery; Mice; Mice, Nude; Sarcoma - drug therapy; Sarcoma - surgery; Vincristine - pharmacology; Xenograft Model Antitumor Assays
• ISSN: 0959-4973; 1473-5741
• DOI: 10.1097/CAD.0000000000001114

Surgical tumor removing is the most common procedure after a confirmed cancer diagnosis with no detected metastasis. Surgery can reduce tumor burden and address pathologic changes caused by local compression of tissues by the tumor. This lowers the chances of tumor cell spreading and creates more favorable conditions for further treatment. However, not all tumor cells can be eliminated through surgery. Even in the early stages of the disease, tumor cells often metastasize and cannot be identified by current detection methods. These tiny, disseminated tumors are often the cause of tumor recurrence. There is currently a lack of effective treatment options that can completely prevent tumor recurrence after surgery. To simulate the actual clinical situation, we selected murine-derived tumor cell lines S180 and Kcc853 to establish a post-transplantation residual tumor model in mice. Surgery was performed on mice inoculated with tumors. Tumor tissue was partially excised to set up the postsurgical residual tumor models. The model simulated the clinical situation where tumor cells were not completely eliminated or there were small tumors that had metastasized before surgery. IL-12 was injected to observe its effect on residual tumors or metastatic microtumors. The administration of IL-12 after surgery can significantly inhibit the growth of residual tumors and metastasis, improve the postoperative tumor-free rate and address the problem of tumor recurrence caused by the growth of residual tumors and micro-metastasis. Therefore, the use of IL-12 antitumor cytokine combined with surgery can effectively inhibit tumor recurrence. Low-dose IL-12 (1–10 ng/kg in humans) can inhibit residual tumor growth.